Figure 1
T-cell-dependent antitumor effects of LTX-315. (a) Anticancer activity of LTX-315 activity on small MCA205 sarcoma. Three intratumoral daily consecutive injections of 300 μg of LTX-315 were performed in 20–25 mm2 established MCA205 sarcomas evolving in C57BL/6 immunocompetent mice. Tumor growth kinetics are depicted (a, left panel). The percentages of tumor-free mice is shown at day 60 (a, middle panel). After a rechallenge of tumor-free mice with the MTD of EL4 or MCA205, the tumor growth were monitored over time (a, right panel). (b) Idem as in a but treating bigger tumors of 35–40 mm2 size. Tumor growth kinetics (left panel) and weight at killing (right panel) are depicted. (c) Bilateral tumor inoculation in the right and left flank four days apart and local injection of LTX-315 only in the first (older, day 8 established) tumor. Tumor sizes for all animals are shown at killing in the ipsilateral (treated, left panel) and contralateral (untreated, right panel) sites. (d) Effects of depleting antibodies targeting CD4 and CD8a molecules on the tumoricidal activity of LTX-315. Tumor growth kinetics in the presence or absence of such specific antibodies (GK1.5 and 53–6.72, 200 μg per mouse) or isotype control mAbs injected. (e) LTX-315 antitumor effects against B16F10 s.c. melanoma. Idem as in a (left panel) following inoculation of the MTD of B16F10. In all graphs, a representative experiment out of two comprising 6–7 mice per group is shown. Student's t-test: *P<0.05, **P<0.01, ***P<0.001; NS, not significant
